Differentiation of benign from metastatic adrenal masses in patients with renal cell carcinoma on contrast-enhanced CT

Kohei Sasaguri, Naoki Takahashi, Mitsuru Takeuchi, Rickey E. Carter, Bradley C. Leibovich, Akira Kawashima

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective. The purpose of this article was to determine whether imaging features on contrast-enhanced CT can differentiate benign from metastatic adrenal masses in patients with renal cell carcinoma (RCC). MATERIALS AND METHODS. Between January 2008 and January 2014, 135 patients with untreated RCC were found to have 163 adrenal masses (102 benign and 61 metastatic) on contrast-enhanced CT including the corticomedullary phase (66 benign and 42 metastatic) or nephrographic phase (56 benign and 33 metastatic) or both. Imaging features of renal and adrenal masses were recorded, including T and N staging components of renal masses, internal texture, CT attenuation values, and attenuation differences between renal and adrenal masses. Logistic regression diagnostic models to differentiate benign from metastatic adrenal mass were constructed using independently signifcant imaging parameters in the respective corticomedullary and nephrographic phases (corticomedullary phase model and nephrographic phase model). Diagnostic performance of the models was evaluated by ROC analysis. RESULTS. Statistically signifcant variables for the models were regional lymphadenopathy, perirenal or renal sinus fat invasion (corticomedullary phase model only), adrenal mass size, CT attenuation value of adrenal mass, and absolute value of attenuation difference between renal and adrenal masses. Both models had excellent diagnostic performance; the AUC and optimal sensitivity and specifcity for the diagnosis of metastasis were 0.991, 100%, and 92.4%, respectively, in the corticomedullary phase model and 0.947, 81.8%, and 96.4%, respectively, in the nephrographic phase model. CONCLUSION. Differentiation between benign and metastatic adrenal masses in patients with RCC can be achieved accurately by combining multiple imaging features on contrast-enhanced CT.

Original languageEnglish (US)
Pages (from-to)1031-1038
Number of pages8
JournalAmerican Journal of Roentgenology
Volume207
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Renal Cell Carcinoma
Kidney
ROC Curve
Area Under Curve
Logistic Models
Fats
Regression Analysis
Neoplasm Metastasis

Keywords

  • Adrenal
  • CT
  • Diagnosis
  • Metastasis
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Differentiation of benign from metastatic adrenal masses in patients with renal cell carcinoma on contrast-enhanced CT. / Sasaguri, Kohei; Takahashi, Naoki; Takeuchi, Mitsuru; Carter, Rickey E.; Leibovich, Bradley C.; Kawashima, Akira.

In: American Journal of Roentgenology, Vol. 207, No. 5, 01.11.2016, p. 1031-1038.

Research output: Contribution to journalArticle

Sasaguri, Kohei ; Takahashi, Naoki ; Takeuchi, Mitsuru ; Carter, Rickey E. ; Leibovich, Bradley C. ; Kawashima, Akira. / Differentiation of benign from metastatic adrenal masses in patients with renal cell carcinoma on contrast-enhanced CT. In: American Journal of Roentgenology. 2016 ; Vol. 207, No. 5. pp. 1031-1038.
@article{263cb61a153b40eb88bd8dd4ca2f9184,
title = "Differentiation of benign from metastatic adrenal masses in patients with renal cell carcinoma on contrast-enhanced CT",
abstract = "Objective. The purpose of this article was to determine whether imaging features on contrast-enhanced CT can differentiate benign from metastatic adrenal masses in patients with renal cell carcinoma (RCC). MATERIALS AND METHODS. Between January 2008 and January 2014, 135 patients with untreated RCC were found to have 163 adrenal masses (102 benign and 61 metastatic) on contrast-enhanced CT including the corticomedullary phase (66 benign and 42 metastatic) or nephrographic phase (56 benign and 33 metastatic) or both. Imaging features of renal and adrenal masses were recorded, including T and N staging components of renal masses, internal texture, CT attenuation values, and attenuation differences between renal and adrenal masses. Logistic regression diagnostic models to differentiate benign from metastatic adrenal mass were constructed using independently signifcant imaging parameters in the respective corticomedullary and nephrographic phases (corticomedullary phase model and nephrographic phase model). Diagnostic performance of the models was evaluated by ROC analysis. RESULTS. Statistically signifcant variables for the models were regional lymphadenopathy, perirenal or renal sinus fat invasion (corticomedullary phase model only), adrenal mass size, CT attenuation value of adrenal mass, and absolute value of attenuation difference between renal and adrenal masses. Both models had excellent diagnostic performance; the AUC and optimal sensitivity and specifcity for the diagnosis of metastasis were 0.991, 100{\%}, and 92.4{\%}, respectively, in the corticomedullary phase model and 0.947, 81.8{\%}, and 96.4{\%}, respectively, in the nephrographic phase model. CONCLUSION. Differentiation between benign and metastatic adrenal masses in patients with RCC can be achieved accurately by combining multiple imaging features on contrast-enhanced CT.",
keywords = "Adrenal, CT, Diagnosis, Metastasis, Renal cell carcinoma",
author = "Kohei Sasaguri and Naoki Takahashi and Mitsuru Takeuchi and Carter, {Rickey E.} and Leibovich, {Bradley C.} and Akira Kawashima",
year = "2016",
month = "11",
day = "1",
doi = "10.2214/AJR.16.16193",
language = "English (US)",
volume = "207",
pages = "1031--1038",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "5",

}

TY - JOUR

T1 - Differentiation of benign from metastatic adrenal masses in patients with renal cell carcinoma on contrast-enhanced CT

AU - Sasaguri, Kohei

AU - Takahashi, Naoki

AU - Takeuchi, Mitsuru

AU - Carter, Rickey E.

AU - Leibovich, Bradley C.

AU - Kawashima, Akira

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Objective. The purpose of this article was to determine whether imaging features on contrast-enhanced CT can differentiate benign from metastatic adrenal masses in patients with renal cell carcinoma (RCC). MATERIALS AND METHODS. Between January 2008 and January 2014, 135 patients with untreated RCC were found to have 163 adrenal masses (102 benign and 61 metastatic) on contrast-enhanced CT including the corticomedullary phase (66 benign and 42 metastatic) or nephrographic phase (56 benign and 33 metastatic) or both. Imaging features of renal and adrenal masses were recorded, including T and N staging components of renal masses, internal texture, CT attenuation values, and attenuation differences between renal and adrenal masses. Logistic regression diagnostic models to differentiate benign from metastatic adrenal mass were constructed using independently signifcant imaging parameters in the respective corticomedullary and nephrographic phases (corticomedullary phase model and nephrographic phase model). Diagnostic performance of the models was evaluated by ROC analysis. RESULTS. Statistically signifcant variables for the models were regional lymphadenopathy, perirenal or renal sinus fat invasion (corticomedullary phase model only), adrenal mass size, CT attenuation value of adrenal mass, and absolute value of attenuation difference between renal and adrenal masses. Both models had excellent diagnostic performance; the AUC and optimal sensitivity and specifcity for the diagnosis of metastasis were 0.991, 100%, and 92.4%, respectively, in the corticomedullary phase model and 0.947, 81.8%, and 96.4%, respectively, in the nephrographic phase model. CONCLUSION. Differentiation between benign and metastatic adrenal masses in patients with RCC can be achieved accurately by combining multiple imaging features on contrast-enhanced CT.

AB - Objective. The purpose of this article was to determine whether imaging features on contrast-enhanced CT can differentiate benign from metastatic adrenal masses in patients with renal cell carcinoma (RCC). MATERIALS AND METHODS. Between January 2008 and January 2014, 135 patients with untreated RCC were found to have 163 adrenal masses (102 benign and 61 metastatic) on contrast-enhanced CT including the corticomedullary phase (66 benign and 42 metastatic) or nephrographic phase (56 benign and 33 metastatic) or both. Imaging features of renal and adrenal masses were recorded, including T and N staging components of renal masses, internal texture, CT attenuation values, and attenuation differences between renal and adrenal masses. Logistic regression diagnostic models to differentiate benign from metastatic adrenal mass were constructed using independently signifcant imaging parameters in the respective corticomedullary and nephrographic phases (corticomedullary phase model and nephrographic phase model). Diagnostic performance of the models was evaluated by ROC analysis. RESULTS. Statistically signifcant variables for the models were regional lymphadenopathy, perirenal or renal sinus fat invasion (corticomedullary phase model only), adrenal mass size, CT attenuation value of adrenal mass, and absolute value of attenuation difference between renal and adrenal masses. Both models had excellent diagnostic performance; the AUC and optimal sensitivity and specifcity for the diagnosis of metastasis were 0.991, 100%, and 92.4%, respectively, in the corticomedullary phase model and 0.947, 81.8%, and 96.4%, respectively, in the nephrographic phase model. CONCLUSION. Differentiation between benign and metastatic adrenal masses in patients with RCC can be achieved accurately by combining multiple imaging features on contrast-enhanced CT.

KW - Adrenal

KW - CT

KW - Diagnosis

KW - Metastasis

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84992655523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992655523&partnerID=8YFLogxK

U2 - 10.2214/AJR.16.16193

DO - 10.2214/AJR.16.16193

M3 - Article

C2 - 27556736

AN - SCOPUS:84992655523

VL - 207

SP - 1031

EP - 1038

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 5

ER -